

Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)

Luke JJ¹, Merchan JR², Hughes B³, Sosman JA⁴, Tripathi A⁵, Puzanov I⁶, Marron T⁷, Johnson M⁸, Marrone K⁹, Powers AS¹⁰, Hill CM¹¹, Janc J¹¹, Rudnick J¹¹, Hu S¹¹, Munneke B¹¹, Mahabhashyam S¹¹, Miller RA¹¹

¹UPMC Hillman Cancer Center, Pittsburgh PA USA, ¹Royal Brisbane and Women's Hospital and University of Oklahoma City OK USA, ¹Roswell Park Cancer Institute, Buffalo NY USA, and University of Oklahoma City OK USA, ¹Roswell Park Cancer Institute, Buffalo NY USA, and University of Oklahoma City OK USA, and University ⁷Mount Sinai Hospital, New York NY USA, ⁸Sarah Cannon Research Institute, Nashville TN USA, ⁹Johns Hopkins University, Baltimore MD USA, ¹⁰Roche Tissue Diagnostics, Tucson AZ USA, ¹¹Corvus Pharmaceuticals, Burlingame CA USA


MUPADOLIMAB, ANTI-CD73 ANTIBODY, BLOCKS CD73 ENZYMATIC ACTIVITY AND ACTIVATES B AND T CELLS





estored T cell proliferation in a subset of donors but did not reach the magnitude of mupadolimab response

MUPADOLIMAB ENHANCES ANTIBODY RESPONSE TO SARS-CoV-2 AND INFLUENZA ANTIGENS



	2 mg/kg + SOC (N=15)	1 mg/kg + SOC (N=14)	Placebo + SOC (N=11)			
Primary Endpoint						
Free from Respiratory Failure or Death (%)	93.3	85.7	81.1			
Secondary Endpoints						
Median Days to Improvement (95% CI)	7.0 (4-9)	5.5 (3-14)	11.0 (2-14)			
Median Days Sustained Improve (95% CI)	8.0 (4-12)	6.0 (3-14)	11.0 (2-21)			
Median Days to Discharge (95% CI)	6.0 (4-12)	4.0 (2-5)	7.0 (2-12)			

• A randomized, placebo controlled, double-blind, multicenter, stratified study of a single dose of mupadolimab (1 mg/kg and 2 mg/kg) plus standard of care (SOC) versus placebo plus SOC was conducted in mild to moderately symptomatic hospitalized COVID-19 patients (NCT04734873).4

• Consistent trend in improved clinical outcome measures seen in treatment arms. Anti-viral antibody response studies consistent with proposed mechanism.

CPX-016 4000 –

MUPADOLIMAB ACTIVATES B CELLS AND PROMOTES DIFFERENTATION^{1,3}

Left panel: In vitro studies show mupadolimab upregulates MHC-II and CD86 on B lymphocytes, suggesting potential for increased antigen presentation. Middle panel: Increased cell surface expression of markers consistent with B cell differentiation into plasma cells. Right panel: B cell activation is unique to mupadolimab as other anti-CD73 antibodies do not induce CD69 expression.

1 3 5 1 3 5 1 3 5 1 3 5

Days After Mupa Stimulation

MUPADOLIMAB INDUCES MORPHOLOGICAL CHANGES MUPADOLIMAB INDUCED B CELL ACTIVATION CONSISTENT WITH B CELL DIFFERENTIATION³ IS ADENOSINE INDEPENDENT¹ Mupa + NECA (0.1 μM)

CD73 EXPRESSION IN VARIOUS CANCERS


CD73 Immunohistochemistry Staining


	Membrane	Cytoplasm	Stroma
HNSCC (N=31)			
HPV+	1/25	2/25	25/25
HPV-	0/6	0/6	6/6
NSCLC (N=75)	42/75	19/75	74/75

patient tumor biospies were examined by IHC (number patient samples positive/number patient samples tested). Calculated by H score, a weighted average of the 4 categories = 3x% 3+ staining + 2x% 2+ staining + 1x% of 1+ staining + 0x% 0 staining, giving a range of 0 to 300. Positivity defined by H score above 100. All NSCLC are adenocarcinoma. In normal lung (N=3, data not included), rare to infrequent staining mostly associated with vessels was observed.

 Nearly all NSCLC patient samples demonstrate stromal staining; subsets also show staining of tumor membrane and

 All HNSCC patient samples examined show stromal staining and rare cases have membrane and cytoplasmic staining. HPV status does not appear to affect stromal expression of





IHC of NSCLC demonstrating stromal and tumor cell staining; IHC of HNSCC demonstrates stromal staining and minimal tumor staining. S = Stroma, T = Tumor


PHASE 1/1B PROTOCOL DESIGN SUMMARY

antagonist) and/or pembrolizumab is being evaluated in patients with advanced refractory cancers. These studies have shown Phase 1 dose escalation portion of the study are shown below. Fifteen NSCLC patients and ten HNSCC patients received doses of ≥ 12 mg/kg. Additional NSCLC and HNSCC patients are being evaluated in ongoing expansion cohorts.

PHARMACOKINETICS AND PHARMACODYNAMICS³

SUSTAINED CD73 OCCUPANCY OF PERIPHERAL BLOOD AT ≥ 12 MG/KG






 Mupadolimab occupancy of peripheral blood B cells was evaluated using flow cytometry and showed complete saturation at trough levels (Day 21).

 Shown below, administration of mupadolimab caused changes in circulating B cells and T cells consistent with redistribution. Only CD73 positive B cells were affected. This supports presence of CD73 engaged by mupadolimab drives

 Each data point represents a patient. Red data points (below) are patients who exhibited low levels of CD73 pretreatment (<20%) expression.

TREATMENT INDUCED RAPID CHANGES IN BLOOD B AND T CELLS

B-cell Dynamics (≥ 12 mg/kg) p < 0.0001 p < 0.0001 p < 0.01



HNSCC AND NSCLC PATIENT CHARACTERISTICS AND ADVERSE EVENT SUMMARY


Patient Characteristics

		Subject Count	Age (yrs), Median (range)	Gender, male N (%)	No. of prior therapies Median (range)	Prior PD-(L)1 Therapy N (%)
HNSC	\mathbb{C}	10	65 (43, 87)	9 (90)	3 (1, 5)	10 (100)
NSCLO		15	64 (53, 80)	6 (40)	3 (2, 4)	14 (93)

Adverse Event Summary

- Treatment related adverse events (AEs) were reported in 17 (68%) of the NSCLC and HNSCC patients.
- Severe AEs (Grade 3 or above) were reported in 4 (16%) patients.
- Treatment related serious AEs were reported in 2 (8%) patients. • No changes in serum quantitative immunoglobulins were observed.

ANTI-TUMOR ACTIVITY IN HNSCC AND NSCLC



Cifo = ciforadenant (A2AR antagonist), pembro = pembrolizumab (anti-PD-1), atezo = atezolizumab (anti-PD-L1), bev = bevacizumab (anti-VEGF), chemo = chemotherapy, nivo = nivolumab (anti-PD-1), PD = progressive disease, SD = stable disease, PR = partial response.

• Waterfall plot of best tumor response seen in Phase 1 portion of the study for evaluable patients. Treatment regimens are indicated.

• Responses were compared to best response of most recent therapy prior to receiving mupadolimab.

• Tumor regression was observed in some patients who had progressive disease as best response to most recent prior therapy, which often included an anti-PD-(L)1 (see yellow highlighted PDs).

• Enrollment in expansion cohorts of NSCLC and HNSCC is ongoing.

CONCLUSIONS

- Mupadolimab is a humanized anti-CD73 antibody that blocks adenosine production.
- Mupadolimab has immunomodulatory activities:
- It induces B cell activation and differentiation into plasmablasts that is adenosine independent
- It augments T cell function by blocking adenosine production
- In humanized mice receiving SARS-CoV-2 and influenza antigens, mupadolimab enhances humoral anti-viral responses, suggesting its potential application as an anti-viral therapy or vaccine adjuvant.
- The enhancement of humoral immunity by mupadolimab is being explored as a potential immunotherapy for various cancers, including virally associated malignancies.
- to be exclusively stromal.

• CD73 expression is high in NSCLC; expression can be membrane, cytoplasm and/or stromal. HNSCC expression of CD73 appears

- In a Phase 1 study, doses of mupadolimab 12 mg/kg or greater are well tolerated, and demonstrate full occupancy of the target. • Mupadolimab binding to CD73 results in transient reductions in circulating B and T cells and is likely a result of redistribution of lymphocytes in to peripheral lymphoid tissues.
- In this Phase 1 study, tumor regression was observed in patients with HNSCC and NSCLC treated with mupadolimab or combinations, including patients who were refractory (progressive disease as best response) to their most recent prior regimen, which often contained an anti-PD-(L)1.

REFERENCES

- 1. Luke JJ, et al. Presented at the ASCO Annual Meeting; May 30-Jun 3, 2019; Chicago, IL, USA. Abstr 2505. 2. Silber, et al. *J Clin Invest*. 1975;56(5):1324-7.
- 3. Luke JJ, et al. Presented at the SITC Annual Meeting; Nov 6-Nov 10, 2019; National Harbor, MD, USA. Abstr O40. 4. Miller RA, et al. *medRxiv*. 2021; doi: https://doi.org/10.1101/2021.09.13.21263406

